MSH6 and ovarian cancer: They are also more likely to be diagnosed at an earlier stage (P = .0041).87 Ten‐year ovarian cancer‐specific survival has been found to be 80.6% in one series of MMR pathogenic variant carriers with ovarian cancer.88 High mRNA expression of MSH6, MLH1, and PMS2 is associated with a significantly improved OS.89 It has been suggested these patients could be good candidates for checkpoint inhibitors.87